APUS

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

425 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Subject)

8-K/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

NT 10-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

Rejects Allegations of MindWave Innovations, Inc. SEOUL, South Korea, March 25, 2026 (GLOBE NEWSWIRE) --  Inscobee Inc. ("Inscobee") and Apimeds, Inc., ("Apimeds Korea") today announced that on March 20, 2026, Inscobee and Apimeds Korea, together with other stockholders of Apimeds Pharmaceuticals US, Inc. (the "Company") (NYSE:APUS) who beneficially own at least 66 2/3% of the voting power of the Company, delivered an action by written consent of the stockholders to the Company (the "Written Consent") to remove Elona Kogan, Jakap Koo, Carol O'Donnell and Dr. Bennett Weintraub as directors of the board of directors of the Company, effective immediately. In addition, pursuant to the Written

MindWave Innovations Inc., a Delaware corporation and wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. ("APUS" or the "Company") (NYSE:APUS), today announced that on March 20, 2026, Inscobee Inc. (KS:006490) and its wholly owned subsidiary Apimeds Inc. (together, "Inscobee"), in concert with certain other stockholders, filed an Amendment No. 2 to Schedule 13D with the Securities and Exchange Commission purporting to effect a hostile takeover of the Company's Board of Directors by written consent. Inscobee claims to have removed all four sitting directors of APUS and installed three hand-picked replacements without notice to the Company, without authorization from the Company as

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

425 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Subject)

8-K/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

Apimeds Pharmaceuticals US, Inc. and Lōkahi Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Addiction Medicine and Pain Medicine (DAAP) has confirmed a Type C meeting to discuss LT-100 (Apitox), a non-opioid biologic candidate being developed for the treatment of the signs and symptoms of osteoarthritis (OA). The meeting will be conducted via teleconference on Monday, May 4, 2026. The scheduled interaction follows the recent submission of a Type C meeting request and represents an important step in the coordinated U.S. regulatory strategy for LT-100. The meeting is intended to support alignment with the FDA on key development

SCHEDULE 13G - Apimeds Pharmaceuticals US, Inc. (0001894525) (Subject)

PREM14C - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- E.F. Hutton is proud to have served as an Exclusive M&A Advisor in the recently completed merger between Apimeds Pharmaceuticals US Inc. (NYSE:APUS) and Mindwave Innovations Inc. The merger brings together a biotech development platform with an AI-powered digital treasury infrastructure supported by a $100 million PIPE commitment, for which E.F. Hutton acted as Placement Agent. E.F. Hutton's involvement underscores its commitment to advancing the combined company's strategic growth across late-stage biotech development and institutional Digital Asset Treasury Solutions. E.F. Hutton worked closely with both companies to shape the transaction fram

Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) today announced the closing of its previously announced $100 million private investment in public equity (PIPE) financing. This substantial investment reinforces the Company's financial position and propels its late-stage non-opioid therapeutic programs toward key clinical and regulatory milestones. The financing also facilitates the integration of MindWave Innovations Inc., aligning corporate operations and financial management processes. As part of that integration, approximately 1,000 Bitcoin previously held by MindWave have been transferred into a segregated, risk-managed structure. This digital-asset position is governed under a defined inv

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

8-K/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

425 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Subject)

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) announced a merger with MindWave Innovations Inc, uniting Apimeds' late-stage, non-opioid pain-management biologic portfolio with MindWave's AI-driven Bitcoin treasury, digital asset yield generation, and $NILA-powered ecosystem. The combined company integrates high-growth biotechnology and institutional digital-treasury capabilities, with the merger supported by a simultaneous PIPE of up to $100 million to advance Apimeds' clinical programs and expand MindWave's digital asset infrastructure. (NYSE:APUS) Apimeds Pharmaceuticals US, Inc. ("Apimeds"), a clinical-stage biotechnology company that completed its IPO in May 2025, today announced that i

4/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)